A study of lung cancer DNA monitoring to predict recovery
Part of Cancer, Lungs & breathing clinical trials.
This study is for people with non-small cell lung cancer who can have curative treatment. It looks for tiny bits of cancer DNA in blood after treatment to see if it helps predict if the cancer comes back. It tests how often to check for this DNA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be a specific type called non-small cell lung cancer
- If your cancer is stage IB to III, it must be removable by surgery, with or without chemo or radiation before surgery
- Or your cancer must be stage III and treatable with a combination of chemo and radiation
- You must be 18 years or older
- You must be able to provide tissue from your cancer and blood samples
- You must not have another active cancer (unless it was removed and is very early or low-risk)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial is testing whether new blood tests can reliably detect and monitor stage III non-small cell lung cancer (NSCLC). It hopes to improve how doctors track your cancer and decide on treatment.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
Hear when a new NSCLC, Stage I, II, III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.